Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
SpringWorks Therapeutics Inc has a consensus price target of $62.33 based on the ratings of 6 analysts. The high is $76 issued by HC Wainwright & Co. on August 28, 2024. The low is $45 issued by B of A Securities on December 1, 2022. The 3 most-recent analyst ratings were released by JP Morgan, HC Wainwright & Co., and HC Wainwright & Co. on September 4, 2024, August 28, 2024, and June 4, 2024, respectively. With an average price target of $72.67 between JP Morgan, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 81.12% upside for SpringWorks Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for SpringWorks Therapeutics (NASDAQ:SWTX) was reported by JP Morgan on September 4, 2024. The analyst firm set a price target for $68.00 expecting SWTX to rise to within 12 months (a possible 69.49% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for SpringWorks Therapeutics (NASDAQ:SWTX) was provided by JP Morgan, and SpringWorks Therapeutics maintained their overweight rating.
There is no last upgrade for SpringWorks Therapeutics
There is no last downgrade for SpringWorks Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on September 4, 2024 so you should expect the next rating to be made available sometime around September 4, 2025.
While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a maintained with a price target of $64.00 to $68.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $40.12, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.